AstraZeneca is a global, innovation and research-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, renal, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

AstraZeneca operates in over 100 countries. The innovative portfolio of medicines of AstraZeneca are used by millions of patients worldwide. AstraZeneca is working across biologics, small molecules, immuno- and nucleotide therapies, protein engineering and devices.

The company has 61,100 employees and invested 5.8 bnUSD in R&D in 2017, more than a quarter of the total revenues. Two of the three strategic R&D centres are located in Europe, in Cambridge UK and Gothenburg Sweden.

The third R&D hub is located in Gaithersburg, MD, US. AstraZeneca has approximately 8,400 employees in the R&D organisation.

AstraZeneca is currently involved in more than 25 ongoing IMI1 and IMI2 projects including EHDEN, COMBACTE-MAGNET and GetReal.